Investor Updates

19. December 2007
Roche´s Full Year Results and Report for 2007
Roche will publish its Full Year Results for 2007 prior to the opening of the Swiss Stock Exchange at 7.00 CET / 6.00 GMT ... more

19. December 2007
Avastin approved in Europe for first-line treatment of patients with advanced kidney cancer
Roche`s innovative anti-cancer drug, was approved today in Europe for the first-line treatment of patients with advanced renal ... more

17. December 2007
Pilot study opens the door for Avastin use in curative setting for women with breast cancer
Roche in collaboration with Genentech commit to large phase III adjuvant clinical programme set to unlock Avastin`s potential ... more

17. December 2007
Addition of Xeloda to Herceptin and docetaxel allows patients with breast cancer to live five months longer without their cancer growing
New data presented today at the San Antonio Breast Cancer Symposium (SABCS) show that adding Xeloda (capecitabine) to the ... more

17. December 2007
Herceptin improves survival in women with advanced HER2-positive breast cancer requiring additional treatment
Studies show breast cancer patients benefit from continued use of Herceptin after progression of the disease more

14. December 2007
MabThera Receives Positive Opinion in Europe for Combination with Any Chemotherapy Regimen in First-Line Treatment for Follicular Non-Hodgkin`s Lymphoma
Roche announced today that the European Union`s Committee on Human Medical Products (CHMP) has given a positive recommendation ... more

14. December 2007
Avastin and Xeloda receive positive recommendations for label extensions in Europe for treatment of advanced colorectal cancer
Roche has received positive recommendations for the Marketing Authorisation extensions for both its anti-angiogenic agent ... more

14. December 2007
Chugai announces approval of anti-cancer agent Xeloda for new indication of postoperative adjuvant chemotherapy for colon cancer
Dear Investor, Please find attached Chugai`s announcement today regarding the approval of Xeloda in the new indication of ... more

14. December 2007
Chugai announces the launch of anti-cancer agent Tarceva in Japan
Dear Investor, Please find attached Chugai´s press release sent out today announcing the launch of Tarceva in Japan. Please ... more

11. December 2007
MabThera improves response in patients with most common form of adult leukaemia
Higher response rates seen in untreated and relapsed CLL patients Early results from two phase II trials tracking the outcome ... more

06. December 2007
Genentech provides update from Avastin FDA Advisory Meeting
Genentech announced today that the Oncologic Drugs Advisory Committee (ODAC) appointed by the U.S. Food and Drug Administration ... more

27. November 2007
Presentational changes of Roche's operating results for 2007
Effective 1 January 2007 the Roche Group is revising the presentation of its operating results. The Group is making these ... more

21. November 2007
Roche Submits Application for FDA Approval of Actemra for the Treatment of Rheumatoid Arthritis
Actemra is the first humanized interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody seeking approval to treat rheumatoid ... more

16. November 2007
Avastin receives positive opinion in Europe for first-line treatment of patients with advanced kidney cancer
- Avastin offers patients the chance to live twice as long without their disease advancing - Avastin now recommended in four ... more

15. November 2007
FDA approves Mircera: first renal anemia treatment in the US with monthly maintenance dosing
Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Mircera (methoxy polyethylene glycol-epoetin ... more

14. November 2007
Roche Confirms Commencement of Due Diligence with Ventana
Roche (SWX: ROG.VX; RO.S) confirmed today that it has entered into a confidentiality agreement with Ventana Medical Systems, ... more

13. November 2007
Roche signs licensing and settlement agreements for Hepatitis C immunodiagnostics
Roche announced today licensing and settlement agreements with Ortho-Clinical Diagnostics, Inc. and Novartis Vaccines & ... more

13. November 2007
Global phase III study of Avastin and Tarceva in metastatic pancreatic cancer reports promising clinical outcome despite primary endpoint not met
Efficacy of Tarceva in this difficult to treat disease was reconfirmed more

08. November 2007
New Actemra data shows significant benefit for patients suffering from Rheumatoid Arthritis
TOWARD study, presented at major US congress ACR, confirms IL-6 receptor inhibition plays a key role in the treatment of ... more

02. November 2007
Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C; -Nucleoside polymerase inhibitor demonstrates >99% mean decrease in HCV RNA with no serious adverse events
more

02. November 2007
Treatment with Pegasys provides hepatitis C patients a second chance to achieve a cure after not responding to Peg-Intron
This landmark study also shows response at 12 weeks is a powerful predictor of eventual treatment success more

02. November 2007
Roche`s Oral Polymerase Inhibitor Shows Robust Antiviral Efficacy in Treatment of Chronic Hepatitis C
R1626, one of Roche`s new investigational drugs for hepatitis C (HCV), has shown promising antiviral efficacy when given in ... more

02. November 2007
Significant new data on Roche`s PEGASYS and Hepatitis C Pipeline compounds to be featured at 58th Annual AASLD Meeting
Roche today announced that new study results for PEGASYS (peginterferon alfa-2a), the world`s leading treatment for chronic ... more

02. November 2007
Reminder: Invitation to event on Roche data & results at ACR 2007 and Roche`s emerging new franchise in autoimmune diseases Friday, November 9, 2007
We kindly invite investors and analysts to participate in an event to present and discuss new data and results presented during ... more

29. October 2007
Reminder: Roche`s Investor and Analyst Briefing on our Hepatitis Franchise at AASLD Monday, 5th November, 2007
We are pleased to invite you to Roche's Analyst Briefing at the Annual Meeting of the American Association for the Study ... more

25. October 2007
Latest data confirm that boosted Invirase provides HIV patients with improved lipid profile with efficacy comparable to Kaletra
Final 48 week results from the international `GEMINI` head-to-head trial, presented today at the 11th European AIDS Conference ... more

24. October 2007
Roche announces positive results in solid tumors using human monoclonal antibody against IGF-1R (R1507)
Today, Roche announced positive results from a Phase I trial of R1507, a human monoclonal antibody to target IGF-1R (insulin-like ... more

23. October 2007
Roche Considering Legal Options In Patent Litigation Case
Roche announced today that a jury in the U.S. District Court in Massachusetts found in favour of Amgen in the patent infringement ... more

22. October 2007
Tarceva approved for lung cancer in Japan
Roche, Chugai and OSI Pharmaceuticals, Inc. announced today that Tarceva (erlotinib) has been approved in Japan for the treatment ... more

19. October 2007
European licence for Roche HIV drug Viracept re-established by European Commission
Roche announced today that the European Commission (EC) has re-instated the Viracept marketing authorization following its ... more

19. October 2007
Pivotal Mircera study first to convert dialysis patients from frequent dosing directly to once every four weeks
MAXIMA findings in The Lancet affirm ability to maintain haemoglobin levels with less frequent dosing more

16. October 2007
Japanese Red Cross selects Roche as partner for nucleic acid screening of entire Japanese blood supply
Unique cobas test system for simultaneous detection of HIV and Hepatitis in donated blood more

16. October 2007
Strong sales growth in the first nine months of 2007 - full-year outlook and Core Earnings per Share target reaffirmed
Group sales up 12% in local currencies to 33.9 billion Swiss francs. As anticipated, Tamiflu sales decline significantly in ... more

15. October 2007
Reminder: Roche`s Third Quarter Sales 2007 Conference Call - Tuesday, October 16th, 2007
Roche will publish its Sales Results for the 3rd Quarter of 2007 prior to the opening of the Swiss Stock Exchange on Tuesday, ... more

12. October 2007
Invitation to event on Roche data & results at ACR 2007 and Roche's emerging new franchise in autoimmune diseases Friday, November 9, 2007
We kindly invite investors and analysts to participate in an event to present and discuss new data and results presented during ... more

05. October 2007
Roche`s Investor and Analyst Briefing on our Hepatitis Franchise at AASLD Monday, 5th November, 2007
We are pleased to invite you to Roche`s Analyst Briefing at the Annual Meeting of the American Association for the Study of ... more

02. October 2007
Jürgen Schwiezer named new CEO Division Roche Diagnostics - Succession to take effect as of January 1, 2008
Roche today announced that Jürgen Schwiezer, currently Roche Diagnostics' president for the EMEA region (Europe, ... more

26. September 2007
Herceptin eradicates tumours and may reduce the need for mastectomies in women with inflammatory HER2-positive breast cancer - one of the most aggressive and fastest growing forms of the disease
New data show that the addition of Herceptin (trastuzumab) to chemotherapy prior to breast cancer surgery (neoadjuvant therapy) ... more

25. September 2007
Positive Xeloda five-year overall survival study data in the adjuvant treatment of colon cancer presented at leading European cancer meeting
Five-year follow-up overall survival data from the X-ACT (Xeloda in Adjuvant Colon Cancer Trial) study show that oral chemotherapy ... more

24. September 2007
Avastin achieves impressive rate of complete resections (R0) in patients with advanced colorectal cancer
Largest series of patients with successful surgery reported in large, prospective clinical trial. New data from the large ... more

20. September 2007
European licence for Roche HIV drug Viracept recommended for re-instatement
Measures put in place to restart the manufacturing and supply of HIV medicine more

20. September 2007
New study shows once-monthly Boniva is as clinically effective as once-weekly Fosamax at increasing bone mineral density in postmenopausal women with osteoporosis
Women with postmenopausal osteoporosis receiving once-monthly Boniva (ibandronate sodium) achieved clinically comparable increases ... more

20. September 2007
Roche wins first Financial Times / Citi Private Bank Environmental Award and was reselected for inclusion in the Dow Jones Sustainability Indexes
Roche announced today that it has been awarded the first Financial Times / Citi Private Bank Environmental Award as the company ... more

17. September 2007
Roche´s Third Quarter Sales 2007 Conference Call - Tuesday, October 16th, 2007
Roche will publish its Sales Results for the 3rd Quarter of 2007 prior to the opening of the Swiss Stock Exchange on Tuesday, ... more

10. September 2007
R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers more

24. August 2007
Genentech announces resubmission of supplemental Biologics License Application for Avastin in combination with paclitaxel for first-line metastatic breast cancer
Please find attached a Genentech news release announcing that the company resubmitted a supplemental Biologics License Application ... more

24. August 2007
Avastin approved in Europe for first-line treatment of patients with advanced lung cancer
First medicine shown to extend survival beyond one year in previously untreated lung cancer patients more

13. August 2007
Roche and Actavis agree on product transactions
Divestment of three Roche pharmaceutical products to Actavis underlines strong focus on key therapy areas more

31. July 2007
Full reconciliation of Chugai interim results into IFRS
Results of Chugai as consolidated by the Roche Group Following the publication of Chugai`s official 2007 interim results, ... more

25. July 2007
Roche Announces Expiration of HSR Waiting Period for Ventana Offer
Roche (SWX: ROG.VX; RO.S), a world-leading healthcare provider of pharmaceuticals and diagnostics, today announced that the ... more

25. July 2007
Actemra monotherapy demonstrates significant clinical benefit in patients with rheumatoid arthritis
- Fourth phase III study with novel interleukin-6 receptor inhibitor meets primary endpoint - Global regulatory filing on ... more

23. July 2007
Smaller size capsules of flu drug Tamiflu receive positive opinion in Europe
more

20. July 2007
Avastin receives positive opinion in Europe for first-line treatment of patients with advanced lung cancer
more

19. July 2007
Severin Schwan to succeed Franz B. Humer as Chief Executive of the Roche Group at the March 2008 shareholders meeting
more

19. July 2007
Roche in the first half of 2007: Strong performance continues
more

18. July 2007
Reminder: Roche´s Half Year Results for 2007
more

11. July 2007
Roche says offer for Ventana Medical Systems, Inc. is full and fair
more

10. July 2007
Actemra: latest phase III study shows significant improvement in symptoms of patients with rheumatoid arthritis
more

09. July 2007
Roche and Alnylam form major alliance on RNAi therapeutics
more

02. July 2007
Avastin shows impressive results for surgery with curative intent in initially unresectable first-line metastatic colorectal cancer patients
more

27. June 2007
Preliminary results for phase III study evaluating CellCept in lupus nephritis
more

27. June 2007
Roche completes acquisition of BioVeris
more

25. June 2007
Roche makes offer to acquire Ventana for 75 US dollars per share in cash
more

25. June 2007
Roche and Toyama Chemical enter licensing agreement to develop potential breakthrough drug to treat rheumatoid arthritis
more

25. June 2007
Once-monthly Mircera keeps haemoglobin stable
more

25. June 2007
Once monthly Mircera could save about 50% of the time health professionals spend on anaemia management in dialysis centres each year
more

19. June 2007
Roche´s Half Year Results for 2007
more

19. June 2007
Roche acquires NimbleGen to gain entry into high-growth research microarrray market
more

15. June 2007
Actemra: Roche´s novel rheumatoid arthritis drug shows substantial benefits for patients in OPTION study
more

13. June 2007
Latest data show MabThera provides significant and sustained relief from signs and symptoms of rheumatoid arthritis
more

07. June 2007
Reminder: Roche´s Analyst Briefing on data presented at EULAR
more

07. June 2007
Innovative new anaemia drug MIRCERA demonstrates ability to maintain tight haemoglobin levels at once monthly dosing in dialysis patients with chronic kidney disease
more

06. June 2007
Roche recalls Viracept due to chemical impurity
more

06. June 2007
Actemra: New data confirms significant improvement of disease signs and symptoms in patients with rheumatoid arthritis
more

05. June 2007
Large clinical trial of Avastin plus FOLFIRI reports promising progression-free survival data
more

04. June 2007
Genentech provides update on pipeline agents at the American Society of Clinical Oncology Meeting
more

03. June 2007
Investigational cancer drug Pertuzumab shows promising results in advanced breast cancer when combined with Herceptin
more

03. June 2007
Herceptin used pre-operatively can eradicate the tumour in nearly twice as many patients as chemotherapy alone
more

03. June 2007
MabThera significantly extends survival and cures more patients with aggressive lymphoma than chemotherapy alone
more

02. June 2007
Avastin significantly prolongs progression free survival in patients with advanced lung cancer
more

02. June 2007
Avastin significantly prolongs progression free survival in advanced kidney cancer
more

25. May 2007
Reminder: Roche´s Investors and Analysts Briefing on data presented at ASCO
more

25. May 2007
Mircera receives positive opinion in Europe for the treatment of anaemia due to chronic kidney disease
more

24. May 2007
Roche ASCO planner
more

21. May 2007
Roche receives approvable letter for Mircera in the United States
more

15. May 2007
Roche´s Analyst Briefing on data presented at EULAR Friday, 15th June, 2007
more

03. May 2007
Roche´s Investors and Analysts Briefing on data presented at ASCO
more

03. May 2007
Herceptin approved in Europe for use in combination with an aromatase inhibitor for the treatment of patients with HER2 and hormone receptor-co-positive metastatic breast cancer
more

02. May 2007
Rituxan phase II data in patients with relapsing-remitting multiple sclerosis presented at the American Academy of Neurology
more

19. April 2007
Roche files Avastin for advanced renal cell cancer
more

18. April 2007
Breakthrough cancer drug Avastin approved in Japan for use in advanced or recurrent colorectal cancer
more

18. April 2007
Roche posts strong first quarter sales - upgrade of Core Earnings per Share outlook for 2007
more

17. April 2007
REMINDER: Roche´s First Quarter Sales 2007 Conference Call
more

17. April 2007
Roche files for Avastin and Xeloda label extension in Europe for treatment of advanced colorectal cancer
more

11. April 2007
Roche and Transgene enter partnership on therapeutic vaccines against HPV-mediated diseases
more

04. April 2007
Roche to acquire BioVeris to expand its leading ECL immunochemistry business into new market segments
more

02. April 2007
Roche acquires THP to expand its therapeutic antibody research
more

30. March 2007
Xeloda approved in Europe for the treatment of advanced stomach cancer
more

29. March 2007
Avastin approved in Europe for first line treatment of women with metastatic breast cancer
more

29. March 2007
Roche acquires 454 Life Sciences to strengthen presence in ultra-fast gene sequencing
more

27. March 2007
Roche submits application to the FDA for use of XELOX (Xeloda plus oxaliplatin) with or without Avastin for the treatment of advanced colorectal cancer
more

26. March 2007
Herceptin receives positive opinion in Europe for use in combination with an aromatase inhibitor for the treatment of patients with HER2- and hormone receptor-positive metastatic breast cancer
more

19. March 2007
Roche´s First Quarter Sales 2007 Conference Call
more

16. March 2007
Combination therapy of Pegasys plus Copegus launched in Japan for patients with chronic hepatitis C
more

06. March 2007
FDA Accepts for Review Two Roche Diagnostics HPV Tests
more

05. March 2007
Roche raises dividend by 36 percent
more

26. February 2007
Positive recommendation for Avastin use in advanced or recurrent colorectal cancer in Japan
more

23. February 2007
Recruitment temporarily suspended into C.E.R.A. Phase II oncology trial
more

23. February 2007
Oral cancer drug Xeloda receives positive opinion from the European Authorities for the treatment of advanced gastric cancer
more

23. February 2007
Avastin receives positive opinion in Europe for first-line treatment of women with metastatic breast cancer
more

22. February 2007
New phase III study confirms positive outcome of Avastin in patients with advanced lung cancer
more

20. February 2007
Roche and GSK agree on two transactions
more

16. February 2007
Quick and easy to use cobas h 232 portable cardiac marker system for cardiovascular diagnoses launched
more

07. February 2007
Roche posts outstanding results for 2006
more

06. February 2007
Reminder - Roche´s Full Year Results and Report for 2006
more

05. February 2007
Roche continues to strengthen Research and Development
more

29. January 2007
Tarceva : European approval for pancreatic cancer treatment
more

26. January 2007
Copegus approved in Japan as combination therapy with Pegasys for patients with chronic hepatitis C
more

24. January 2007
First Actemra multinational phase III trial demonstrates significant improvement in signs and symptoms of rheumatoid arthritis
more

22. January 2007
New phase III data highlights excellent efficacy of Roche´s cancer drugs Xeloda and Avastin for treatment of advanced colorectal cancer
more

10. January 2007
NeoRecormon gains European approval for convenient once weekly treatment of anaemia in patients with solid cancers
more

09. January 2007
Roche´s Full Year Results and Report for 2006
more

05. January 2007
The Lancet journal today announces the first publication of the full length data of the HERA trial as they were presented at the American Society of Clinical Oncology (ASCO) medical congress in May 2006.
more

05. January 2007
Positive results from a randomized phase II study of Pertuzumab in combination with Gemcitabine for advanced ovarian cancer
more